<DOC>
	<DOCNO>NCT00104975</DOCNO>
	<brief_summary>RATIONALE : Giving low dos chemotherapy donor peripheral blood stem cell transplant help stop growth cancer cell . It also stop patient 's immune system reject donor 's stem cell . The donated stem cell may replace patient 's immune system help destroy remain cancer cell ( graft-versus-tumor effect ) . Giving infusion donor 's T cell treat laboratory transplant may help increase effect . Sometimes transplanted cell donor also make immune response body 's normal cell . Giving tacrolimus transplant may stop happen . PURPOSE : This phase I trial study side effect best dose donor lymphocyte give alemtuzumab combination chemotherapy treat patient undergo donor stem cell transplant hematologic cancer .</brief_summary>
	<brief_title>Alemtuzumab Combination Chemotherapy Followed By Donor Lymphocytes Treating Patients Who Are Undergoing Donor Stem Cell Transplant Hematologic Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine feasibility efficacy reduced-intensity condition regimen comprise alemtuzumab , fludarabine , melphalan , thiotepa follow allogeneic peripheral blood stem cell transplantation ( PBSCT ) patient hematologic malignancy . - Determine toxicity regimen patient . - Determine safety LMB-2 immunotoxin-treated , selectively-depleted donor T cell , administer allogeneic PBSCT , patient . OUTLINE : This dose-escalation study LMB-2 immunotoxin-treated , selectively-depleted donor T cell . - T cell preparation : Patients donor undergo apheresis obtain peripheral blood mononuclear cell ( PBMCs ) , expanded culture . Patients ' PBMCs irradiate mixed donor PBMCs . LMB-2 immunotoxin add PBMCs order selectively deplete T cell donor PBMCs . - Conditioning : Patients receive alemtuzumab IV 2 hour day -9 -5 , fludarabine IV 30 minute day -8 -5 , melphalan IV 15-20 minute day -4 , thiotepa IV day -3 -2 . - Immunosuppression : Patients receive tacrolimus IV continuously day -10 1 . - Allogeneic peripheral blood stem cell ( PBSC ) transplantation : Patients undergo allogeneic PBSC transplantation day 0 . - LMB-2 immunotoxin-treated , selectively-depleted donor T cell : Patients receive LMB-2 immunotoxin-treated , selectively-depleted donor T cell IV 30-60 minute approximately day 28 . Cohorts 3-6 patient receive escalate dose LMB-2 immunotoxin-treated , selectively-depleted donor T cell maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 6 patient experience dose-limiting-toxicity . After completion study treatment , patient follow weekly 100 day post-transplantation periodically survival . PROJECTED ACCRUAL : A total 15-20 patient accrue study .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<mesh_term>Myelodysplastic-Myeloproliferative Diseases</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Thiotepa</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Alemtuzumab</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis 1 follow hematologic malignancy : Chronic myelogenous leukemia Accelerated phase blast phase Acute myeloid leukemia , meet follow criterion : In second subsequent remission In primary induction failure In partial remission In resistant relapse Chronic lymphocytic leukemia In Richter 's transformation Highgrade nonHodgkin 's lymphoma Refractory standard treatment Myeloproliferative disorder Undergoing transformation terminal stage Myelodysplastic syndrome ( MDS ) , include follow : Refractory anemia excess blast Transformation acute leukemia MDS secondary chemotherapy Partiallymatched relate family donor available One HLA haplotype match No HLAmatched ( 10/10 9/10 ) sibling donor unrelated donor available NOTE : A new classification scheme adult nonHodgkin 's lymphoma adopt PDQ . The terminology `` indolent '' `` aggressive '' lymphoma replace former terminology `` low '' , `` intermediate '' , `` high '' grade lymphoma . However , protocol us former terminology . PATIENT CHARACTERISTICS : Age 18 55 Performance status ECOG 01 Life expectancy Not specify Hematopoietic Not specify Hepatic SGOT SGPT &lt; 3 time upper limit normal ( ULN ) No active persistent viral hepatitis Renal Creatinine &lt; 2.0 mg/dL* OR Creatinine clearance &gt; 60 mL/min* NOTE : *Unless due malignancy Cardiovascular LVEF ≥ 45 % Pulmonary DLCO ≥ 60 % predicted* ( correct hemoglobin ) NOTE : *Unless patient give clearance pulmonary consultation Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 2 year completion study treatment HIV negative Human T cell lymphotrophic virus type 1 negative No serious comorbid medical condition No medical condition would preclude study compliance PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy Not specify Endocrine therapy Not specify Radiotherapy Not specify Surgery Not specify</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>accelerated phase chronic myelogenous leukemia</keyword>
	<keyword>recurrent adult Burkitt lymphoma</keyword>
	<keyword>stage IV adult Burkitt lymphoma</keyword>
	<keyword>recurrent adult lymphoblastic lymphoma</keyword>
	<keyword>stage IV adult lymphoblastic lymphoma</keyword>
	<keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage IV adult immunoblastic large cell lymphoma</keyword>
	<keyword>refractory anemia excess blast transformation</keyword>
	<keyword>refractory anemia excess blast</keyword>
	<keyword>secondary myelodysplastic syndrome</keyword>
	<keyword>chronic myelomonocytic leukemia</keyword>
	<keyword>blastic phase chronic myelogenous leukemia</keyword>
	<keyword>chronic eosinophilic leukemia</keyword>
	<keyword>primary myelofibrosis</keyword>
	<keyword>chronic neutrophilic leukemia</keyword>
	<keyword>essential thrombocythemia</keyword>
	<keyword>polycythemia vera</keyword>
	<keyword>adult acute myeloid leukemia remission</keyword>
	<keyword>adult acute myeloid leukemia 11q23 ( MLL ) abnormality</keyword>
	<keyword>adult acute myeloid leukemia inv ( 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 15 ; 17 ) ( q22 ; q12 )</keyword>
	<keyword>adult acute myeloid leukemia ( 16 ; 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 8 ; 21 ) ( q22 ; q22 )</keyword>
	<keyword>recurrent adult acute myeloid leukemia</keyword>
	<keyword>refractory chronic lymphocytic leukemia</keyword>
	<keyword>stage III chronic lymphocytic leukemia</keyword>
	<keyword>stage IV chronic lymphocytic leukemia</keyword>
	<keyword>stage III adult Burkitt lymphoma</keyword>
	<keyword>stage III adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage III adult lymphoblastic lymphoma</keyword>
	<keyword>myelodysplastic/myeloproliferative neoplasm , unclassifiable</keyword>
	<keyword>de novo myelodysplastic syndrome</keyword>
	<keyword>previously treat myelodysplastic syndrome</keyword>
	<keyword>atypical chronic myeloid leukemia , BCR-ABL1 negative</keyword>
</DOC>